drugset / Trial / NCT01099358
Study in Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelOther
Summary
The primary purpose of this study is to help answer the following research question(s): * To see how the body absorbs, processes, and gets rid of cetuximab when the drug is taken in combination with cisplatin \[pharmacokinetic (PK) analysis\] * To see if any drug interactions occur between cetuximab and cisplatin.
Timeline
- Start
- 2010-04
- Primary completion
- 2015-10
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 400 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 1000 mg/m2 | Intravenous |